Ceapro (CRPOF)(CZO) – Potential Therapy for Pulmonary Fibrosis in COVID-19 Patients

Wednesday, May 27, 2020

Ceapro (CRPOF)(CZO)

Potential Therapy for Pulmonary Fibrosis in COVID-19 Patients

Ceapro, Inc. is a publicly-held (TSX-V: CZO, OTCQX: CRPOF) Canadian biotechnology company developing and commercializing “active ingredients” for the healthcare and cosmetic industries. Ceapro’s active ingredients are primarily derived from oats and other renewable plant resources. The Company utilizes its proprietary plant extraction-based manufacturing process to supply active ingredients based on “oat beta glucan and avenanthramides”. Ceapro has patented a technology known as “Pressurized Gas eXpanded (PGX) technology”, which has superior features when compared to conventional drying and purification technologies. Using PGX technology, Ceapro generates novel biopolymers and biocomposites with micro/nanoparticles.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ceapro expands collaboration with McMaster University. Under the new collaboration agreement, Ceapro will sponsor the development of an inhalable therapeutic based on “PGXprocessed yeast beta glucan” (PGX-YBG) for the treatment of pulmonary fibrosis in COVID19 patients. In preclinical models, PGX-YBG has shown immunomodulatory properties.

    Versatility of Ceapro’s proprietary PGX Technology. PGX technology utilizes the unique properties of a PGX liquid consisting of pressurized carbon dioxide and ethanol to dry aqueous polymer solutions at mild operating conditions in a spray chamber, which allows the production of ultra thin, high value biopolymers with multiple medical and…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Potential Therapy for Pulmonary Fibrosis in COVID-19 Patients

Wednesday, May 27, 2020

Ceapro (CRPOF)(CZO)

Potential Therapy for Pulmonary Fibrosis in COVID-19 Patients

Ceapro, Inc. is a publicly-held (TSX-V: CZO, OTCQX: CRPOF) Canadian biotechnology company developing and commercializing “active ingredients” for the healthcare and cosmetic industries. Ceapro’s active ingredients are primarily derived from oats and other renewable plant resources. The Company utilizes its proprietary plant extraction-based manufacturing process to supply active ingredients based on “oat beta glucan and avenanthramides”. Ceapro has patented a technology known as “Pressurized Gas eXpanded (PGX) technology”, which has superior features when compared to conventional drying and purification technologies. Using PGX technology, Ceapro generates novel biopolymers and biocomposites with micro/nanoparticles.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ceapro expands collaboration with McMaster University. Under the new collaboration agreement, Ceapro will sponsor the development of an inhalable therapeutic based on “PGXprocessed yeast beta glucan” (PGX-YBG) for the treatment of pulmonary fibrosis in COVID19 patients. In preclinical models, PGX-YBG has shown immunomodulatory properties.

    Versatility of Ceapro’s proprietary PGX Technology. PGX technology utilizes the unique properties of a PGX liquid consisting of pressurized carbon dioxide and ethanol to dry aqueous polymer solutions at mild operating conditions in a spray chamber, which allows the production of ultra thin, high value biopolymers with multiple medical and…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Neovasc (NVCN)(NVCN:CA) – Neovasc Removes Financing Overhang

Wednesday, May 27, 2020

Neovasc (NVCN)(NVCN:CA)

Neovasc Removes Financing Overhang

As of April 24, 2020, Noble Capital Markets research on Neovasc is published under ticker symbols (NVCN and NVCN:CA). The price target is in USD and based on ticker symbol NVCN. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Neovasc Inc is a specialty medical device company. The company develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina. Neovasc is developing the Tiara for the treatment of mitral valve disease. Neovasc operates its business in one segment.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Retiring 2017 Notes. Neovasc’s management yesterday provided a corporate update and announced several agreements, including a $5 mm financing, and the retirement of 2017 Notes (which had onerous provisions), which we believe improves the Company’s financial position and revamps its capital structure.

The Reducer for the Treatment of Refractory Angina. Neovasc is seeking FDA approval to commercialize the Reducer for the treatment of refractory angina in the United States. Management indicated that Pre-Market Approval (PMA) review is progressing as expected. The Company just…



Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Continues to Solidify NG-911 Offerings with New Acquisition

Wednesday, May 27, 2020

Comtech Telecommunications Corp. (CMTL)

Continues to Solidify NG-911 Offerings with New Acquisition

Comtech Telecommunications Corp. engages in the design, development, production, and marketing of products, systems, and services for advanced communications solutions in the United States and internationally. It operates in three segments: Telecommunications Transmission, Mobile Data Communications, and RF Microwave Amplifiers. The Telecommunications Transmission segment provides satellite earth station equipment and systems, over-the-horizon microwave systems, and forward error correction technology, which are used in various commercial and government applications, including backhaul of wireless and cellular traffic, broadcasting (including HDTV), IP-based communications traffic, long distance telephony, and secure defense applications. The Mobile Data Communications segment provides mobile satellite transceivers, and computers and satellite earth station network gateways and associated installation, training, and maintenance services; supplies and operates satellite packet data networks, including arranging and providing satellite capacity; and offers microsatellites and related components. The RF Microwave Amplifiers segment designs, develops, manufactures, and markets satellite earth station traveling wave tube amplifiers (TWTA) and broadband amplifiers. Its amplifiers are used in broadcast and broadband satellite communication; defense applications, such as telecommunications systems and electronic warfare systems; and commercial applications comprising oncology treatment systems, as well as to amplify signals carrying voice, video, or data for air-to-satellite-to-ground communications. The company serves satellite systems integrators, wireless and other communication service providers, broadcasters, defense contractors, military, governments, and oil companies. Comtech markets its products through independent representatives and value-added resellers. The company was founded in 1967 and is headquartered in Melville, New York.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New Acquisition. Yesterday, Comtech announced it had acquired NG-911, Inc., a pioneer of next generation 911 solutions for public safety agencies in the Midwest. Terms of the deal were not made public and the financial impact of the acquisition is not material. In connection with the deal, Comtech was awarded several contracts to deploy the Company’s Solacom’s Guardian Call Handling solutions to the 9-1-1 Northern Illinois Next Generation Alliance Consortium valued at more than $15 million over a multi-year period.

    Solidifying NG-911 Position. The acquisition of NG-911 continues to expand and solidify Comtech’s next generation 911 position, in our view. In February, Comtech was selected to provide a Guardian Next Generation 9-1-1 call handling solution to the Northwest Central Dispatch System, an intergovernmental consolidated emergency dispatch system providing 9-1-1 services for several communities in northwest suburban Chicago and received a $ 6.6 million award to upgrade a statewide NG 9-1-1 system for a New England state. Last year, the Company acquired Solacom, received a $100 million NG-911 award from Massachusetts, and…




    Click to get the full report.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Comtech Telecommunications Corp. (CMTL) – Continues to Solidify NG-911 Offerings with New Acquisition

Wednesday, May 27, 2020

Comtech Telecommunications Corp. (CMTL)

Continues to Solidify NG-911 Offerings with New Acquisition

Comtech Telecommunications Corp. engages in the design, development, production, and marketing of products, systems, and services for advanced communications solutions in the United States and internationally. It operates in three segments: Telecommunications Transmission, Mobile Data Communications, and RF Microwave Amplifiers. The Telecommunications Transmission segment provides satellite earth station equipment and systems, over-the-horizon microwave systems, and forward error correction technology, which are used in various commercial and government applications, including backhaul of wireless and cellular traffic, broadcasting (including HDTV), IP-based communications traffic, long distance telephony, and secure defense applications. The Mobile Data Communications segment provides mobile satellite transceivers, and computers and satellite earth station network gateways and associated installation, training, and maintenance services; supplies and operates satellite packet data networks, including arranging and providing satellite capacity; and offers microsatellites and related components. The RF Microwave Amplifiers segment designs, develops, manufactures, and markets satellite earth station traveling wave tube amplifiers (TWTA) and broadband amplifiers. Its amplifiers are used in broadcast and broadband satellite communication; defense applications, such as telecommunications systems and electronic warfare systems; and commercial applications comprising oncology treatment systems, as well as to amplify signals carrying voice, video, or data for air-to-satellite-to-ground communications. The company serves satellite systems integrators, wireless and other communication service providers, broadcasters, defense contractors, military, governments, and oil companies. Comtech markets its products through independent representatives and value-added resellers. The company was founded in 1967 and is headquartered in Melville, New York.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New Acquisition. Yesterday, Comtech announced it had acquired NG-911, Inc., a pioneer of next generation 911 solutions for public safety agencies in the Midwest. Terms of the deal were not made public and the financial impact of the acquisition is not material. In connection with the deal, Comtech was awarded several contracts to deploy the Company’s Solacom’s Guardian Call Handling solutions to the 9-1-1 Northern Illinois Next Generation Alliance Consortium valued at more than $15 million over a multi-year period.

    Solidifying NG-911 Position. The acquisition of NG-911 continues to expand and solidify Comtech’s next generation 911 position, in our view. In February, Comtech was selected to provide a Guardian Next Generation 9-1-1 call handling solution to the Northwest Central Dispatch System, an intergovernmental consolidated emergency dispatch system providing 9-1-1 services for several communities in northwest suburban Chicago and received a $ 6.6 million award to upgrade a statewide NG 9-1-1 system for a New England state. Last year, the Company acquired Solacom, received a $100 million NG-911 award from Massachusetts, and…




    Click to get the full report.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Neovasc Removes Financing Overhang

Wednesday, May 27, 2020

Neovasc (NVCN)(NVCN:CA)

Neovasc Removes Financing Overhang

As of April 24, 2020, Noble Capital Markets research on Neovasc is published under ticker symbols (NVCN and NVCN:CA). The price target is in USD and based on ticker symbol NVCN. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Neovasc Inc is a specialty medical device company. The company develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina. Neovasc is developing the Tiara for the treatment of mitral valve disease. Neovasc operates its business in one segment.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Retiring 2017 Notes. Neovasc’s management yesterday provided a corporate update and announced several agreements, including a $5 mm financing, and the retirement of 2017 Notes (which had onerous provisions), which we believe improves the Company’s financial position and revamps its capital structure.

The Reducer for the Treatment of Refractory Angina. Neovasc is seeking FDA approval to commercialize the Reducer for the treatment of refractory angina in the United States. Management indicated that Pre-Market Approval (PMA) review is progressing as expected. The Company just…



Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Genprex Inc. (GNPX) – Emerging as a Leader in Cancer Gene Therapy

Tuesday, May 26, 2020

Genprex Inc.(GNPX)

Emerging as a Leader in Cancer Gene Therapy

Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Unique Gene Therapy Technology. We believe that Genprex will emerge as a leader in the area of gene therapy for the treatment of cancer. Genprex is developing a unique platform technology consisting of the use of lipid nanoparticles designed to restore normal tumor suppressor protein levels in cancer cells to induce apoptosis (programmed cell death), inhibit tumor progression and prolong survival of cancer patients.

    GEN-001 for the Treatment of Lung Cancer. Genprex’s lead product, GEN-001, in combination with AstraZeneca’s Tagrisso or Merck’s Keytruda, will be evaluated in Phase I/II clinical trials for the treatment of non-small cell lung cancer (NSCLC). Previous clinical results showed a disease control rate (DCR) of….



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Ely Gold Royalties (ELYGF)(ELY:CA) – Visible Growth Drivers

Tuesday, May 26, 2020

Ely Gold Royalties (ELYGF)(ELY:CA)

Visible Growth Drivers

As of April 24, 2020, Noble Capital Markets research on Ely Gold Royalties is published under ticker symbols (ELYGF and ELY:CA). The price target is in USD and based on ticker symbol ELYGF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Ely Gold Royalties Inc is an emerging royalty company with producing and development assets focused in Nevada and the Western US. It offers shareholders a low-risk leverage to the current price of gold and low-cost access to long-term gold royalties.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ely substantially completes acquisition of VEK Associates.  Ely Gold Royalties has substantially completed its acquisition of VEK Associates and has closed on the acquisition of 92.4% of the VEK shares outstanding. The remaining 7.6% of VEK shares are expected to be acquired pending the completion of share transfer documentation. VEK’s principal assets are comprised of five royalty properties, all of which are currently leased. Four of the leases are with Nevada Gold Mines, a joint venture 61.5% owned and operated by Barrick Gold Corporation and 31.5% owned by Newmont Corporation, and the other lease is with SSR Mining Inc.

    Private placement raises C$17,250,00 to fund growth initiatives. On May 21, Ely Gold Royalties closed a brokered private placement offering of 21,562,500 units at a price of C$0.80 per unit for gross proceeds of C$17,250,000. Following the offering, we estimate Ely Gold has 157,286,496 shares outstanding and 197,120,376 on a fully diluted basis. The company intends to use the net proceeds for exploration, royalty acquisitions and…



    Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Visible Growth Drivers

Tuesday, May 26, 2020

Ely Gold Royalties (ELYGF)(ELY:CA)

Visible Growth Drivers

As of April 24, 2020, Noble Capital Markets research on Ely Gold Royalties is published under ticker symbols (ELYGF and ELY:CA). The price target is in USD and based on ticker symbol ELYGF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Ely Gold Royalties Inc is an emerging royalty company with producing and development assets focused in Nevada and the Western US. It offers shareholders a low-risk leverage to the current price of gold and low-cost access to long-term gold royalties.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ely substantially completes acquisition of VEK Associates.  Ely Gold Royalties has substantially completed its acquisition of VEK Associates and has closed on the acquisition of 92.4% of the VEK shares outstanding. The remaining 7.6% of VEK shares are expected to be acquired pending the completion of share transfer documentation. VEK’s principal assets are comprised of five royalty properties, all of which are currently leased. Four of the leases are with Nevada Gold Mines, a joint venture 61.5% owned and operated by Barrick Gold Corporation and 31.5% owned by Newmont Corporation, and the other lease is with SSR Mining Inc.

    Private placement raises C$17,250,00 to fund growth initiatives. On May 21, Ely Gold Royalties closed a brokered private placement offering of 21,562,500 units at a price of C$0.80 per unit for gross proceeds of C$17,250,000. Following the offering, we estimate Ely Gold has 157,286,496 shares outstanding and 197,120,376 on a fully diluted basis. The company intends to use the net proceeds for exploration, royalty acquisitions and…



    Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Emerging as a Leader in Cancer Gene Therapy

Tuesday, May 26, 2020

Genprex Inc.(GNPX)

Emerging as a Leader in Cancer Gene Therapy

Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Unique Gene Therapy Technology. We believe that Genprex will emerge as a leader in the area of gene therapy for the treatment of cancer. Genprex is developing a unique platform technology consisting of the use of lipid nanoparticles designed to restore normal tumor suppressor protein levels in cancer cells to induce apoptosis (programmed cell death), inhibit tumor progression and prolong survival of cancer patients.

    GEN-001 for the Treatment of Lung Cancer. Genprex’s lead product, GEN-001, in combination with AstraZeneca’s Tagrisso or Merck’s Keytruda, will be evaluated in Phase I/II clinical trials for the treatment of non-small cell lung cancer (NSCLC). Previous clinical results showed a disease control rate (DCR) of….



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

How Do Negative Interest Rates Impact Households?

Who Would be Happiest with Negative Interest?

Negative interest rates can be hard to wrap your head around. After all, why would anyone accept earning less than the yield available keeping cash in their mattress? It doesn’t seem to make sense. The first time I experienced rates below 0% was the 2008 financial crisis after Treasury Bills, and even Federal Agency discount notes traded briefly below zero. Those occurrences, 11 years ago, seemed like a once in a lifetime oddity. But they weren’t. Since then, economies around the globe have had below zero interest from time to time, and we’ve become more accustomed to the concept. We used to think that the floor for rates was zero, now we know, in theory, it is infinitely low.

Interest Rate
Basics

The Federal Open Market Committee (FOMC), makes decisions on interest rate targets. These decisions are then implemented by the Federal Reserve Bank of New York (The Fed). Through open market operations, they impact the interest rate level banks charge each other to borrow money overnight (fed funds rate).  They do this primarily by injection of money into the economy by purchasing securities or by taking money out by selling securities. This is how it works. Buying securities adds to money supply; this lowers the price (rates) banks need to pay for reserves. Selling securities takes money out of the system, which makes money tighter and puts upward pressure on rates. The impact of overnight rates and expectations on how long they will stay at a specific target impacts longer-term rate moves. This is the main lever by which The Fed steers the economy by adjusting rate targets.

Historically The Fed raises interest rates to tap the economic brake pedal to keep inflation at bay in a strong economy.  This works because when borrowing costs by business and consumers are higher, demand for goods is reduced.  Should the economy be weakening, The Fed targets a lower rate policy to encourage borrowing, thus spending.

The FOMC has not ever decided that U.S. interest rate policy is best served by negative rates. This is not to say it hasn’t been discussed. The Bank of Japan in its fight with deflation was the first central bank to move to a zero-interest policy (1999), its key overnight rate has been negative since 2016.  Six years ago, the European Central Bank (ECB) adopted a policy of negative interest rates to avert an economic crisis. The ECB slashed its deposit rate to negative 0.1% that year to avert deflationary pressure and to stimulate the economic region. The current ECB deposit rate is negative 0.5%, which is the lowest ever.

How Do Sub-Zero Rates
Fight Deflation?

When the economy slows, consumer spending slows and businesses become more careful with their spending. Without confidence in an improving economic environment there is no reason to increase spending. This has at times led to lower prices and could cause unwanted deflation to become entrenched in the system.  The undesirable cycle starts when spending slows, demand declines, prices fall (to attract buyers), teaching consumers to wait for even lower prices.

Negative rates fight deflation by increasing the costs of holding money while waiting for lower prices. It simply incentivizes spending. The choice for individuals are to keep their money in the bank and watch it become worth nominally less over time or spend it and perhaps even borrow at historically low levels which stimulates the economy

Are Negative Rates in
the Cards for the U.S.?

President Trump has been vocal on the subject of negative rates. He has referred to them as a “gift” for the economy. The Fed, which takes its marching orders from the FOMC, insists negative interest rates are not being considered. Federal Reserve Chairman Jerome Powell is on record as having said, “I continue to think, and my colleagues on the Federal Open Market Committee continue to think that negative interest rates are probably not an appropriate or useful policy for us here in the United States. ” 

The Fed has a number of other tools in its arsenal that it has not been slow to use. For now, it seems clear the fed fund rate target will be zero or above.

How Would Personal Finances
Be Impacted by Negative Rates?

For most, rates directly impact us when we borrow, including credit cards and deposit accounts. The stock market, along with real assets, would also be affected:

Loans — The European experience with rates this low has been high loan demand after implementing negative rates. Denmark’s third-largest lender, Jyske Bank, serviced 10-year loans with a negative 0.5% APR. Nordea Bank, based in Finland, wrote 20-year mortgages at 0%. The risk is that demand is increased, and assets purchased on cash flow increase in value too quickly. 

Credit Cards — The average credit card rate is 16.01%. Negative interest rates would certainly lower credit card terms. This would happen as negative interest rates create more competition between card issuers that make money on the spread between what they pay for money, which would be very low, and what they charge consumers. It is not likely consumer rates would approach zero, but they would be reduced to the point that card users would have more cash in their pockets. More cash could cause increased consumption

Deposit Savings — Yields on savings accounts would be reduced to near zero. When this has happened in the past, banks have then instituted fees that effectively cause depositor returns to drop below zero. One of the primary purposes of negative interest is to encourage spending by those waiting for lower prices. This could draw these people out to make their purchases. Big savers, such as retirees on a fixed-income, keep a high percentage of their “nest egg” in Certificates of Deposit. This age group has been hardest hit in the past as rates approached zero.

Equity & Real Estate
Markets
– 

Low rates have the effect of pushing savers and investors into riskier assets. As cash moves from safer investments to seeking more return, the equity markets could increase with the added demand.  For many, potential earnings are preferable to sure erosion of savings. The actual stimulative impact of the zero and sub-zero rates would take time. The lag could be as much as a year for the cheap money to work its way into asset prices.

Increased activity in real estate
investments could also benefit. Banks will first need to have enough confidence in the economic future to lend, allowing homebuyers and speculators to become buyers. Financially strong borrowers are likely to have access to bank and private borrowing. The increase in real estate activity will put upward pressure on real estate prices. Additionally, large purchases are made based on cash-flow. Lower or negative borrowing rates reduce monthly payments. It would not take long before prices to get bid up by buyers or held high by stubborn sellers.

 

  • Take-Away

Negative interest rates are a monetary policy tool for unprecedented economic times. They have been used to both stimulate economies and fight deflation in other countries. The U.S. has experienced its own market-driven (not policy-driven) negative rates. It should not shock and panic the markets if The Fed adopts a negative interest rate policy. The President has expressed his approval of such a policy.  The Chairman of the Federal Reserve has repeatedly said it’s not looking to implement sub-zero borrowing rates at this time.

The equity markets could benefit as savers reach for potential return rather than sure loss and put more risk in their portfolios. The other asset class that could benefit is real estate. This would be driven by cheap money available in a market that is driven by borrowing

Paul Hoffman

Managing Editor

 

Suggested Reading:

Stock Index
Adjustments and Self-Directed Investors

Climbing the “Wall of
Worry”

The Correlation
between Passive Investing and Underperformance

 

Enjoy Premium Channelchek Content at No Cost

 

Sources:

Short-Term
Yields Go Negative in Scramble for Cash

Asset
allocation in a world of financial repression

Negative interest rates

Negative Rates, designed as a Short-Term Jolt, Have Become an Addiction

Full Transcript: Jerome Powell 60 Minutes Interview

Investment Europe (Nov. 2018)

Creditcards.com

Sierra Metals (SMTS)(SMT:CA) – Thinking Big

Friday, May 22, 2020

Sierra Metals (SMTS)(SMT:CA)

Thinking Big

As of April 24, 2020, Noble Capital Markets research on Sierra Metals is published under ticker symbols (SMTS and SMT:CA). The price target is in USD and based on ticker symbol SMTS. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Sierra Metals Inc is a precious and base metals producer in Latin America. The company acquires, explores, extracts, and produces mineral concentrates consisting of silver, copper, lead, zinc and gold in Mexico and Peru. Its activity includes the operation of the Yauricocha Mine in Peru, and the Bolivar and Cusi mines in Mexico. Yauricocha is an underground polymetallic mine using the sublevel block caving and cut-and-fill mining methods. Bolivar is a copper-silver-zinc-gold underground mine using room-and-pillar mining method. The majority of the revenue is earned by selling of the mineral concentrates to its customers in Peru.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    CEO appointment marks next chapter in Sierra Metals’ development. Sierra Metals appointed Mr. Luis Marchese as Chief Executive Officer effective June 1 replacing Mr. Igor Gonzales whose voluntary resignation is effective May 31. Under Mr. Gonzales, Sierra Metals successfully completed significant production expansions at the Yauricocha, Bolivar and Cusi mines along with associated resource and reserve expansions. We believe Mr. Marchese will build on Mr. Gonzales’ work and broaden the focus to consider strategic partnerships that could help accelerate development of potential large-scale copper porphyry projects that could create significant value for Sierra Metals shareholders. The company has been executing well operationally and Mr. Marchese has an impressive record of successfully championing large scale copper projects and working with multiple strategic partners.

    Capacity expansions support earnings and cash flow growth. Production capacity has increased 57% from processing 5,375 tonnes per day in 2015 to 8,450 tonnes per day in 2019 for a compound annual growth rate of 12.0%. Production capacity is expected to end 2020 at 9,800 tonnes per day with the potential for additional low-cost expansions. While base metals prices are currently low, most of the capital for recent planned expansions has been spent and we expect the company to begin generating…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Thinking Big

Friday, May 22, 2020

Sierra Metals (SMTS)(SMT:CA)

Thinking Big

As of April 24, 2020, Noble Capital Markets research on Sierra Metals is published under ticker symbols (SMTS and SMT:CA). The price target is in USD and based on ticker symbol SMTS. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Sierra Metals Inc is a precious and base metals producer in Latin America. The company acquires, explores, extracts, and produces mineral concentrates consisting of silver, copper, lead, zinc and gold in Mexico and Peru. Its activity includes the operation of the Yauricocha Mine in Peru, and the Bolivar and Cusi mines in Mexico. Yauricocha is an underground polymetallic mine using the sublevel block caving and cut-and-fill mining methods. Bolivar is a copper-silver-zinc-gold underground mine using room-and-pillar mining method. The majority of the revenue is earned by selling of the mineral concentrates to its customers in Peru.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    CEO appointment marks next chapter in Sierra Metals’ development. Sierra Metals appointed Mr. Luis Marchese as Chief Executive Officer effective June 1 replacing Mr. Igor Gonzales whose voluntary resignation is effective May 31. Under Mr. Gonzales, Sierra Metals successfully completed significant production expansions at the Yauricocha, Bolivar and Cusi mines along with associated resource and reserve expansions. We believe Mr. Marchese will build on Mr. Gonzales’ work and broaden the focus to consider strategic partnerships that could help accelerate development of potential large-scale copper porphyry projects that could create significant value for Sierra Metals shareholders. The company has been executing well operationally and Mr. Marchese has an impressive record of successfully championing large scale copper projects and working with multiple strategic partners.

    Capacity expansions support earnings and cash flow growth. Production capacity has increased 57% from processing 5,375 tonnes per day in 2015 to 8,450 tonnes per day in 2019 for a compound annual growth rate of 12.0%. Production capacity is expected to end 2020 at 9,800 tonnes per day with the potential for additional low-cost expansions. While base metals prices are currently low, most of the capital for recent planned expansions has been spent and we expect the company to begin generating…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.